Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.

ABSTRACT:

Background

Despite the high sustained virological response rates achieved with current directly-acting antiviral agents (DAAs) against hepatitis C virus (HCV), around 5-10% of treated patients do not respond to current antiviral therapies, and basal resistance to DAAs is increasingly detected among treatment-naïve infected individuals. Identification of amino acid substitutions (including those in minority variants) associated with treatment failure requires analytical designs that take into account the high diversification of HCV in more than 86 subtypes according to the ICTV website (June 2017).

Methods

The methodology has involved five sequential steps: (i) to design 280 oligonucleotide primers (some including a maximum of three degenerate positions), and of which 120 wer

SUBMITTER: Soria ME 

PROVIDER: S-EPMC6122477 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature